Феринджект чаще вызывает гипофосфатемию, чем монофер, которая может длиться до 5 недель у каждого третьего-четвертого:
The incidence of hypophosphatemia was significantly higher in the ferric carboxymaltose versus the ferumoxytol group (<2.0 mg/dl [0.65 mM], 50.8% vs. 0.9%; <1.3 mg/dl [0.42 mM], 10.0% vs. 0.0%; P < 0.001), and hypophosphatemia persisted through the end of the 5-week study period in 29.1% of ferric carboxymaltose-treated patients versus none of the ferumoxytol-treated patients (P < 0.001).
---
JCI Insight. 2018 Dec 6;3(23).
Randomized trial of intravenous iron-induced hypophosphatemia.
Wolf M. и соавт.
|